Andere talen Brii Biosciences Limited

Aandelen

2137

KYG1645A1094

Vertraagde tijd Hong Kong S.E. Andere beurzen 05:13:02 02-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,02 ^HKD	+0,99%		-4,67%	-55,26%

10/06	Brii Biosciences presenteert gegevens over hepatitis B-medicijn op Europese medische conferentie	MT
07/06	Brii Biosciences Limited kondigt nieuwe gegevens aan van twee fase 2-onderzoeken waarin BRII-179 wordt geëvalueerd	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference	10/06
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024	07/06
Brii Biosciences Limited Announces New Data from Two Phase 2 Studies Evaluating BRII-179	07/06
Brii Bio's Hepatitis B Drugs Get Breakthrough Therapy Designation in China	15/05
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies	14/05
Brii Biosciences Limited Announces Center for Drug Evaluation of the National Medical Products Administration of China Grants Breakthrough Therapy Designations for BRII-877 and BRII-835	14/05
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results	25/03
Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179	05/03
VBI Vaccines Sells Rights to Hepatitis B Vaccine to Brii Biosciences	14/02
Brii Biosciences to Buy Rights to Hepatitis B Vaccine from VBI	14/02
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies	14/02
Brii Biosciences Hires Chief Scientific Officer	04/01
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer	03/01
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer	03/01
Brii Biosciences Presents Hepatitis B Treatment Data at US Liver Disease Conference	14/11
PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023	14/11
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 in Combination with PEG-IFN for the Treatment of Chronic Hepatitis B	07-09-23
Brii Biosciences’ Study Into Therapeutic Vaccine for Chronic Hepatitis B Patients Shows Safety, Tolerability	06-09-23
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B	06-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Brii Biosciences Limited

Aandelen

2137

KYG1645A1094

Andere talen

Filters